CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
Autologous Umbilical Cord Blood Mononuclear Cells Therapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02999373
NCT02999373Phase 2Completed
CompareCT.gov

Autologous Cord Blood Mononuclear Cells for Bronchopulmonary Dysplasia in Very Preterm Neonates

Guangdong Women and Children Hospital·interventional·Posted Dec 21, 2016·Updated Nov 2, 2021

In Brief

A Phase 2 clinical trial evaluating Autologous Umbilical Cord Blood Mononuclear Cells Therapy for Bronchopulmonary Dysplasia and 2 related conditions. Completed, enrolled 62 participants across 1 site.

Detailed Summary

Rationale: Pre-clinical animal studies provide robust evidence regarding the beneficial effect of cord blood-derived mononuclear cells (MNCs) for experimental bronchopulmonary dysplasia (BPD). This single-center, non-randomized, controlled, blinded trial assessed the effect of a single intravenous infusion of autologous cord blood MNCs (ACBMNCs) in preventing BPD in very preterm neonates, a high-risk population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchopulmonary Dysplasia, Premature, Neonatal Death
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 21, 2016
Enrollment StartJul 1, 2018
Primary CompletionJan 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.5 years ago

Interventions

Autologous Umbilical Cord Blood Mononuclear Cells Therapyother

Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection